Gamma glutamyl transferase – an underestimated marker for cardiovascular disease and the metabolic syndrome

Authors

  • Manuela G Neuman In Vitro Drug Safety and Biotechnology and Department of Pharmacology and Toxicology, University of Toronto
  • Stephen Malnick
  • Lucy Chertin

DOI:

https://doi.org/10.18433/jpps30923

Abstract

Gamma glutamyl transferase (GGT) is an enzyme in glutathione and cysteine metabolism. GGT is a standard liver enzyme test reflecting biliary tract involvement. It also has a prooxoidant activity and a modulating influence on endothelia dysfunction. GGT is associated with the metabolic syndrome and is often elevated in patients with NAFLD.

There is also a role for GGT activity in several aspects cardiovascular disease. There is an association between elevated GGT and cardiovascular mortality, atrial fibrillation, exacerbation of congestive heart failure . In addition there is an association with obstructive sleep apnea.

We review the evidence available and suggest that there is a need for further assessing the use of GGT, together with the presence of the metabolic syndrome as a prognostic marker.

Downloads

Download data is not yet available.

Author Biography

Manuela G Neuman, In Vitro Drug Safety and Biotechnology and Department of Pharmacology and Toxicology, University of Toronto

CEO In Vitro Drug Safety and Biotechnology

Downloads

Published

2020-04-19

How to Cite

Neuman, M. G., Malnick, S., & Chertin, L. (2020). Gamma glutamyl transferase – an underestimated marker for cardiovascular disease and the metabolic syndrome. Journal of Pharmacy & Pharmaceutical Sciences, 23(1), 65–74. https://doi.org/10.18433/jpps30923

Issue

Vol. 23 (2020): Pages 1 - 205

Section

Review Articles

License

Copyright (c) 2020 Journal of Pharmacy & Pharmaceutical Sciences

Creative Commons License

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.

This is an open access journal with free of charge non-commercial download. At the time of submission, authors will be asked to transfer the copyright to the accepted article to the Journal of Pharmacy and Pharmaceutical Sciences. The author may purchase the copyright for $500 upon which he/she will have the exclusive copyright to the article. Nevertheless, acceptance of a manuscript for publication in the Journal is with the authors' approval of the terms and conditions of the Creative Commons copyright license Creative Common license (Attribution-ShareAlike) License for non-commercial uses.

CLOCKSS system has permission to collect, preserve, and serve this Archival Unit.